ARCHIVES

Immunotherapy Demonstrates Disease Control in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 9 | September 28, 2012

Download PDF Visit The Full Archive

Related Articles

Was Dr. Bunn Insensitive Or Just Efficient? FDA Imbroglio Points To Larger Problems

November 10, 1995

In Brief: Daniel Nixon Of Emory to Head Prevention Program; Henderson To Get Rosenthal Award

January 30, 1987

NCAB Committee Ok’s Recompetition of OD Support Contract

May 22, 1992

ODAC Oks Carboplatin As 1st Line Ovarian Therapy; Other Drugs

July 12, 1991

AGS-003 Immunotherapy Induces T Cell Responses in Phase II Trial

November 29, 2013

Steven Curley Named Chief of Surgical Oncology At Baylor’s Dan L. Duncan Cancer Center

October 4, 2013